INTRODUCTION
Proper storage, transportation and handling of inactivated foot and mouth disease (FMD) vaccines is necessary for successful vaccination campaigns in areas where the disease is endemic. The shelf life of these vaccines indicated by the manufacturers is usually twelve months under the specified conditions of storage. However, the ultimate shelf life of these vaccines remains to be determined.
In countries where different climatic zones exist and where the vaccine has to be transported over long distances, it is sometimes difficult to meet the specified conditions of storage. At times, in spite of careful shipment, the vaccines are likely to be exposed to elevated temperatures for varying periods during transport before reaching their destination.
The information available on aluminium hydroxide gel-adjuvanted Frenkel type vaccines (2, 3, 5) and vaccines produced by the BHK-21 suspension culture system (6) and oil-adjuvanted vaccines (7) suggests that FMD vaccines retain their potency for a period in excess of their stated shelf life at 4°C. However, their ultimate shelf life as well as the effect of exposure to elevated temperatures on the potency of these vaccines has not been well established.
Here we report the results of potency tests performed with aluminium hydroxide gel-adjuvanted, formaldehyde-inactivated FMD virus vaccines produced at this Institute using the BHK-21 suspension culture system and stored for varying periods at about 4°C and 25°C, respectively.
MATERIALS AND METHODS

Vaccines.
Formaldehyde-inactivated FMD vaccines with saponin and adsorbed to aluminium hydroxide gel were prepared at this Institute from the vaccine strains of subtypes 0 5 , A 5 , A 22 , Cj and Asia 1/1 virus grown in BHK-21 Razi suspension cells in fermentors. Different batches representing the five subtypes of monovalent vaccines were selected for testing.
Potency tests.
Since vaccine potency tests in cattle by challenge are extremely costly, the tests were conducted in guinea-pigs following the C-index method described by Lucam et al. (4) .
For verifying the potency after storage at about 4°C, the initial tests on each batch were conducted shortly after manufacture and the vaccine batches were subsequently held in cold storage at about 4°C. Representative samples for testing from each batch were collected after varying periods of storage at about 4°C. Samples from some batches were tested for their potency before and after exposure to 25°C in an incubator for two days. Table I gives guinea-pig protection (C-index) values for nine batches of vaccine representative of five subtypes stored at about 4°C. It is evident that no appreciable loss of potency was detected after 12-15 months' storage in the case of subtype 0 5 vaccine, after 24 months in the case of A 5 vaccine, after 35 months in the case of A 22 vaccine, after 13-20 months in the case of C vaccine and after 12-22 months in the case of Asia 1/1 vaccine. These results confirm the findings of earlier workers who reported that FMD virus vaccines incorporating European strains of types O, A and C retained their potency well above the minimum required standards under the specified conditions of storage for 18-24 months (6, 7) and in a case of type O vaccine even up to 40 months (2) .
RESULTS AND DISCUSSION
With the type of potency test employed in the present study, the variation around the end-point is expected to be about 1.5 times the observed value. This would explain the apparent increase in potency of Asia 1 vaccine (batch No. 2/79) from C-index of 2.09 to 3.07 after 22 months' storage at about 4°C (Table I) .
Furthermore, there was no appreciable loss of potency in the six batches of vaccine representing the five subtypes tested after storage at 25°C for two days (Table II) should, therefore, be regarded of acceptable potency even after storage under the conditions specified in the present experiment.
The results of these investigations, therefore, confirm that saponified aluminium hydroxide gel-adsorbed, formaldehyde-inactivated FMD virus vaccines produced at this Institute using the BHK-21 suspension cell culture system have good storage properties and may be expected to be efficient even beyond their stated shelf life at about 4°C, though the ultimate shelf life still remains to be determined. These vaccines also retain their potency after storage at 25°C for at least two days. These findings are very important from the point of view of vaccine storage, packing, transport and further handling in the field. However, to retain the maximum potency, the vaccines should be stored and transported at low temperatures (about 4°C) wherever possible. 
